• Profile
Close

12 weeks Ombitasvir/Paritaprevir-ritonavir + Ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis

Digestive and Liver Diseases Feb 18, 2018

Degasperi E, et al. - Safety and efficacy of Ombitasvir/Paritaprevir-ritonavir (OBT/PTV-r) plus Ribavirin (RBV) for 12 weeks were evaluated in real-life hepatitis C virus (HCV)-genotype 4 patients with advanced fibrosis. The authors achieved 100% sustained virological response with 12-weeks of OBT/PTV-r + RBV in HCV-4 patients with the advanced liver disease, including compensated cirrhotics.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay